-VISIT OUR OTHER FORUMS- OB-GYN-L Ultrasound Ultrasound History Fibroid Forum Physicians-in-Training Tech Talk OBSTET-L (portuguese) OBGIN-L (spanish) Nursing

Re: Market Research anecdote From: art fougner, md (evsono@pipeline.com) Thu Jul 12 08:07:23 2001 Messages sorted by: [ date ][ thread ][ subject ][ author ] Next message: art fougner, md: "Re: Market Research anecdote" Previous message: RModugno@aol.com: "Special credentialing" In reply to: Zach Newton: "Market Research anecdote" Next in thread: Steve & Eryl Raymond: "Re: Market Research anecdote" Zach - not evidence-based but put me down for universal and prior to becoming sexually active. virus is ubiquitous. how might vaccination affect hpv typing currently recommended in evaluation of ascus? how oft would be the booster? potential complications ? art At Wed, 11 Jul 2001, Zach Newton wrote: > >Living in Atlanta provides opportunity for invitations for focus group >and one-on-one market research participation, typically for $150-$200 >for an hour's time. I participate frequently. > >Today, the topic was a vaccine for immunity against 4 sub-types of HPV. >For me, an exciting development. Questions asked referenced potential >candidates for product and how such would be identified by practitioner. > >My responses were focused on issue of delivery of vaccine on policy >basis with or without pre-screening for prior infection with targeted >agents. Also, offered the opinion that the greatest efficacy would be >achieved by pre-pubertal administration, as with Hepatitis B >vaccination. > >The application of such a product to the sexually active post pubertal >population is a problem. The cost of pre-screening before vaccination >for eligibility vs universal vaccination regardless of infective status >represents a problem that would demand resolution of the cost/benefit >equation. > >If you were a public health officer or chair of AMA policy committeee, >which way would you go? > >The cost and the horrible impact of positive result in non-infected >patient, more common in low prevalence patient population, represent >huge issues for me. The identification of the candidate for vaccination >in the post-pubertal population is a big problem. > >Who has thoughts? > >-- >Zach Newton >Z. B. Newton, III, M.D. >Atlanta/Gyn > -- art fougner, md A series of 1000 cases begins with but a single anecdote. Next message: art fougner, md: "Re: Market Research anecdote" Previous message: RModugno@aol.com: "Special credentialing" In reply to: Zach Newton: "Market Research anecdote" Next in thread: Steve & Eryl Raymond: "Re: Market Research anecdote"

Return to

Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Dec 2 04:51:07 2009

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.